Lundbeck, Otsuka win EU nod for long-lasting Abilify; Aspen Pharmacare shares slide on GSK stake-sale news;

@FiercePharma: Wednesday's best-read story (still): Will Teva find a partner to save it from itself? More | Follow @FiercePharma

@EricPFierce: 350 sales folks get the ax as Actavis trims US force post Warner Chilcott merger. Story | Follow @EricPFierce

@CarlyHFierce: Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer. Release | Follow @CarlyHFierce

> The Danish pharma company Lundbeck and Japanese partner Otsuka won EU approval for their long-lasting version of the antipsychotic Abilify as a treatment for schizophrenia. Report

> A Madrid court ordered Germany-based Grünenthal, which made the morning sickness drug thalidomide now linked with birth defects, to pay at least €20,000 to each Spanish victim. Report

> Shares in South Africa's Aspen Pharmacare slid almost 4% on the news that GlaxoSmithKline ($GSK) had unloaded a third of its stake in the company. Report

> European austerity moves have cut into healthcare spending since the financial crisis of 2008, particularly in hard-hit markets such as Greece and Italy. Report (sub. req.)

> Johnson & Johnson ($JNJ) is fighting shareholder claims that it paid former CEO Bill Weldon too much. Report

> New research suggests that longtime users of birth control pills may be at higher risk of glaucoma. Report (sub. req.)

> JPMorgan raised its price target on Bayer to €112 from €100. Report

Medical Device News

@FierceMedDev: Medtronic scores promising results for next-gen stent graft. Story | Follow @FierceMedDev

@MarkHFierce: A Belgian company snagged some new funding for an interesting ophthalmic device, tech spun out of a Seattle outfit. Item | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More | Follow @MichaelGFierce

> Myriad partners up with BioMarin for cancer diagnostics. Article

> OraSure dumps Roche for Thermo Fisher in drug abuse Dx development deal. News

> Slumping Hologic downs poison pill as Icahn looms. Report

Biotech News

@FierceBiotech: FDA sets up roadblock for Forest, Richter, rejecting #schizophrenia drug. Story | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline politely dumps $230M Fabry drug deal with Amicus. News | Follow @JohnCFierce

@DamianFierce: Icahn buys into Hologic; Hologic swallows 10% poison pill. Release | Follow @DamianFierce

@EmilyMFierce: Imagining the Post-Antibiotics Future. Feature (via Medium) | Follow @EmilyMFierce

> Pfizer, GlaxoSmithKline forge cancer alliance in combo melanoma trial pact. More

> Flagship Ventures launches a biotech on the human microbiome sea. News

> Array slides as longtime CSO finds the exit. Item

Vaccines News

> European Union prepares to back vaccine stability project. News

> China's climate diversity creates flu vaccination complications. More

> WHO updates malaria roadmap with 2030 vaccine goals. Article

> U.S. gathers vaccine researchers to talk bioterrorism threat Q fever. Story

> CDC to import unapproved Novartis vaccine to stem Princeton meningitis outbreak. Piece

Pharma Manufacturing News

> JLL lines up financing for $2.6B Patheon, DSM deal. More

> GE Oslo plant gets FDA OK for new heart imaging product. News

> Pfizer to close Puerto Rico plant. Story

> Actavis puts California plant on hit list. Article

> Unilife grabs $40M contract to fill Hikma injectables. More

And Finally... Australian drugmaker CSL Ltd. is testing HDL cholesterol infusions as a way to stave off repeat heart attacks. Report